Department of Stomatology, Area of Pathology, Bauru School of Dentistry, University of São Paulo, Alameda Octávio Pinheiro Brisolla, 9-75, Bauru, São Paulo, 17012-901, Brazil.
Adolfo Lutz Institute, Pathology Division, São Paulo, Brazil.
BMC Cancer. 2018 Jan 8;18(1):53. doi: 10.1186/s12885-017-3914-0.
Moesin is a member of the ERM (ezrin, radixin and moesin) proteins that participate in cell migration and tumor invasion through transductional signals sent to actin filaments by glycoproteins, such as podoplanin.
This study aimed to evaluate the participation of moesin and podoplanin in the invasive tumor front of oral squamous cell carcinomas, and their influence on patients' prognosis. Podoplanin and moesin immunoexpressions were evaluated by a semi-quantitative score method, based on the capture of 10 microscopic fields, at 400X magnification, in the invasive tumor front of oral squamous cell carcinomas. The association of moesin and podoplanin expression with clinicopathological variables was analyzed by the chi-square, or Fisher's exact test. The 5 and 10 years survival rates were calculated by the Kaplan-Meier method and the survival curves were compared by using the log-rank test.
The immunohistochemical expression of moesin in the invasive front of oral squamous cell carcinomas was predominantly strong, homogenously distributed on the membrane and in the cytoplasm of tumor cells. The expression of moesin was not associated with clinical, demographic and microscopic features of the patients. Otherwise, podoplanin expression by malignant epithelial cells was predominantly strong and significantly associated with radiotherapy (p = 0.004), muscular invasion (p = 0.006) and lymph node involvement (p = 0.013). Strong moesin expression was considered an unfavorable prognostic factor for patients with oral squamous cell carcinomas, clinical stage II and III (p = 0.024).
These results suggested that strong moesin expression by malignant cells may help to determine patients with oral squamous cell carcinoma and poor prognosis.
Moesin 是 ERM（ezrin、radixin 和 moesin）蛋白家族的成员之一，通过糖蛋白（如 podoplanin）向肌动蛋白丝传递转导信号，参与细胞迁移和肿瘤侵袭。
本研究旨在评估 moesin 和 podoplanin 在口腔鳞状细胞癌侵袭性肿瘤前沿的参与情况及其对患者预后的影响。采用半定量评分法评估 podoplanin 和 moesin 的免疫表达，根据在口腔鳞状细胞癌侵袭性肿瘤前沿的 10 个显微镜视野，在 400X 放大倍数下进行捕获。采用卡方检验或 Fisher 精确检验分析 moesin 和 podoplanin 表达与临床病理变量的关系。采用 Kaplan-Meier 法计算 5 年和 10 年生存率，并采用对数秩检验比较生存曲线。
口腔鳞状细胞癌侵袭前沿的 moesin 免疫组化表达主要为强阳性，均匀分布于肿瘤细胞膜和细胞质。moesin 的表达与患者的临床、人口统计学和显微镜特征无关。另一方面，恶性上皮细胞的 podoplanin 表达主要为强阳性，与放疗（p=0.004）、肌肉浸润（p=0.006）和淋巴结受累（p=0.013）显著相关。强 moesin 表达被认为是口腔鳞状细胞癌、临床分期 II 和 III 期患者的不利预后因素（p=0.024）。
这些结果表明，恶性细胞中强 moesin 表达可能有助于确定口腔鳞状细胞癌患者的预后不良。
